Program Type: New England CEPAC

Obesity Management

Nov 2025 | Assessment

Intervention of Interest For questions please contact info@icer.org. View the Key Stakeholder List.

Retinitis Pigmentosa

Apr 2025 | Assessment

Interventions of Interest ICER assessed the comparative clinical effectiveness and value of sonpiretigene isteparvovec (Nanoscope Therapeautics) for the treatment of advanced retinitis pigmentosa. An independent appraisal committee voted that the current evidence is adequate to demonstrate a net health benefit of sonpiretigene isteparvovec compared to usual care. Final Documents For questions please contact info@icer.org. View […]

Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Nov 2024 | Assessment

Interventions of Interest The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tabelecleucel when compared to usual care; tabelecleucel would achieve common thresholds for cost-effectiveness if priced between $143,900 to $273,700 per treatment cycle. Final Documents For questions or to request a Spanish translated Report-at-a-Glance or ICER […]

Post-Traumatic Stress Disorder

May 2024 | Assessment

Interventions of Interest Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits for MDMA-AP compared to short-term trauma-focused psychotherapies. Click here for “Five Fast Facts on ICER and our PTSD Report.” For questions or to request a Spanish translated Report-at-a-Glance or ICER Snapshot for this assessment, please contact info@icer.org. […]